sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Sugammadex

Medicine

Sugammadex

Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • Additional pediatric use information is approved for Merck Sharp & Dohme LLC's BRIDION ® (sugammadex) injection.
  • However, due to Merck Sharp & Dohme LLC's marketing exclusivity rights, this drug product is not labeled with that information.
Do not take if
  • Sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components.
  • Hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex.

What it is used for

Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. Additional pediatric use information is approved for Merck Sharp & Dohme LLC's BRIDION ® (sugammadex) injection. However, due to Merck Sharp & Dohme LLC's marketing exclusivity rights, this drug product is not labeled with that information.

Side effects, and when to stop

The following serious adverse reactions are described elsewhere in the labeling:

Who should not take it

Sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. Hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Sugammadex; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/sugammadex

APA 7th

sofidex. (2026, August 3). Sugammadex. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/sugammadex

AMA 11th

Sugammadex. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/sugammadex

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.